Patent Assignment
Reel/Frame 049110/0550
Corrective Assignment to Correct the Application Numbers 09402976, 10196590, 11562002,11562173,12047388,13078575,13541314,13541325, 14747289 Previously Recorded on Reel 047322 Frame 0843. Assignor(S) Hereby Confirms the Merger.
Recorded: 2019-05-07
Pages: 19
Assignor
DEPOMED, INC.
Executed: 2018-08-10
Assignee
ASSERTIO THERAPEUTICS, INC.
100 S. SAUNDERS ROAD, SUITE 300, LAKE FOREST, ILLINOIS, 60045
Covered Properties
(122)
Sustained-Release Oral Drug Dosage Form
Patent:
5,007,790 →
Application:
07/336,440 →
Sustained-Release Oral Drug Dosage Form
Application:
08/060,456 →
Alkyl-Substituted Cellulose-Based Sustained-Release Oral Drug Dosage Forms
Application:
08/201,490 →
Alkyl-Substituted Cellulose-Based Sustained-Release Oral Drug Dosage Forms
Patent:
5,582,837 →
Application:
08/453,144 →
Gastric-Retentive Oral Controlled Drug Delivery System with Enhanced Retention Properites
Application:
08/663,588 →
Gastric-Retentive, Oral Drug Dosage Forms for the Controlled-Release of Sparingly Soluable Drugs and Insoluble Matter
Patent:
5,972,389 →
Application:
08/716,906 →
Gastric-Retentive Oral Drug Dosage Forms for Controlled Release of Highly Soluble Drugs
Application:
08/870,509 →
Oral Liquid Compositions
Patent:
6,287,594 →
Application:
09/232,354 →
Extending the Duration of Drug Release Within the Stomach During the Fed Mode
Oral Liquid Compositions
Patent:
6,365,180 →
Application:
09/354,982 →
Pharmacological Inducement of the Fed Mode for Enhanced Drug Administration to the Stomach
Application:
09/432,881 →
Shell-and-core dosage form approaching zero-order drug release
Application:
09/498,945 →
Tablet Shapes to Enhance Gastric Retention of Swellable Controlled-Release Oral Dosage Forms
Patent:
6,488,962 →
Application:
09/598,061 →
Inhibition of Emetic Effect of Metformin with 5-HT3 Receptor Antagonists
Patent:
6,451,808 →
Application:
09/691,398 →
Extending the duration of drug release within the stomach during the fed mode
Application:
09/990,061 →
Publication:
US 2002/0051820
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
Application:
10/014,750 →
Publication:
US 2003/0091630
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
Application:
10/024,932 →
Publication:
US 2003/0104052
Optimal Polymer Mixtures for Gastric Retentive Tablets
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
Application:
10/045,816 →
Extending the Duration of Drug Release Within the Stomach During the Fed Mode
Manufacture of Oral Dosage Forms Delivering Both Immediate-Release and Sustained-Release Drugs
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
Application:
10/152,914 →
Publication:
US 2003/0031711
Shell-And-Core Dosage Form Approaching Zero-Order Drug Release
Pharmacological Inducement of the Fed Mode for Enhanced Drug Administration to the Stomach
Methods of Treatment Using a Gastric Retained Gabapentin Dosage
Methods of Treatment Using a Gastric Retained Losartan Dosage
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
Application:
10/281,284 →
Publication:
US 2003/0133985
Formulation of an erodible, gastric retentive oral diuretic
Application:
10/293,217 →
Publication:
US 2003/0152622
Dual drug dosage forms with improved separation of drugs
Application:
10/623,481 →
Publication:
US 2005/0013863
Gastro-retentive levodopa delivery form
Application:
10/684,058 →
Publication:
US 2004/0180086
Pharmaceutical compositions
Application:
10/753,628 →
Publication:
US 2004/0166067
Gastric Retentive Oral Dosage Form with Restricted Drug Release in the Lower Gastrointestinal Tract
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
Application:
10/773,986 →
Publication:
US 2004/0156899
Methods of Treatment Using a Gastric Retained Gabapentin Dosage
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
Application:
11/322,448 →
Publication:
US 2006/0159743
Gastric retentive gabapentin dosage forms and methods for using same
Application:
11/648,134 →
Publication:
US 2007/0184104
Pulsatile gastric retentive dosage forms
Application:
12/220,747 →
Publication:
US 2009/0028941
Gastric Retained Gabapentin Dosage Form
Gastric Retentive Gabapentin Dosage Forms and Methods for Using Same
Application:
12/331,184 →
Publication:
US 2009/0176882
Methods for Treating Vasomotor Symptoms Using Gaba Analogs in a Gastric Retentive Dosage Form
Method of Treating Post-Surgical Acute Pain
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
Method of Treating Post-Surgical Acute Pain
Gastric Retentive Pharmaceutical Compositions for Treatment and Prevention of Cns Disorders
Methods of Treatment Using a Gastric Retained Gabapentin Dosage
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
Method of Treating Post-Surgical Acute Pain
Gastric Retained Gabapentin Dosage Form
Shell-And-Core Dosage Form Approaching Zero-Order Drug Release
Method of Treating Post-Surgical Acute Pain
Gastric Retentive Pharmaceutical Compositions for Immediate and Extended Release of Levosulpiride
Application:
12/872,529 →
Publication:
US 2011/0052700
Gastric Retentive Pharmaceutical Compositions for Immediate and Extended Release of Acetaminophen
Application:
12/872,723 →
Publication:
US 2011/0052685
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of Acetaminophen and Phenylephrine
Application:
12/940,911 →
Publication:
US 2011/0104272
Gastric Retentive Pharmaceutical Compositions for Immediate and Extended Release of Phenylephrine
Application:
12/940,964 →
Publication:
US 2011/0104273
Gastric Retentive Pharmaceutical Compositions for Extended Release of Polypeptides
Application:
12/963,520 →
Publication:
US 2011/0135728
Methods of Treating Non-Nociceptive Pain States with Gastric Retentive Gabapentin
Application:
13/110,522 →
Publication:
US 2011/0218246
Gastric Retained Gabapentin Dosage Form
Gastric Retentive Oral Dosage Form with Restricted Drug Release in the Lower Gastrointestinal Tract
Shell and Core Dosage Form Approaching Zero-Order Drug Release
Method of Treating Post-Surgical Acute Pain
Gastric Retentive Dosage Forms for Extended Release of Acamprosate into the Upper Gastrointestinal Tract
Methods of Treatment Using a Gastric Retained Gabapentin Dosage
Methods of Treatment Using a Gastric Retained Gabapentin Dosage
Methods of Treatment Using a Gastric Retained Gabapentin Dosage
Gastric Retained Gabapentin Dosage Form
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
Gastric Retained Gabapentin Dosage Form
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
Dual Drug Dosage Forms with Improved Separation of Drugs
Gastric Retained Gabapentin Dosage Form
Gastric Retained Gabapentin Dosage Form
Gastric Retentive Oral Dosage Form with Restricted Drug Release in the Lower Gastrointestinal Tract
Application:
13/684,155 →
Publication:
US 2013/0149379
Methods for Treating Vasomotor Symptoms Using Gaba Analogs in a Gastric Retentive Dosage Form
Application:
13/686,865 →
Publication:
US 2013/0158121
Shell-And-Core Dosage Form Approaching Zero-Order Drug Release
Gastric Retentive Gabapentin Dosage Forms and Methods for Using Same
Gastric Retained Gabapentin Dosage Form
Compositions and Methods for Treating Gastrointestinal Motility Dysfunction
Application:
13/900,312 →
Publication:
US 2013/0316002
Methods of Treatment Using a Gastric Retained Gabapentin Dosage Form
Pharmaceutical Compositions for Extended Release of Azo-Bonded 5-Aminosalicylic Acid Compositions
Application:
14/012,484 →
Publication:
US 2014/0066411
Gastric Retained Gabapentin Dosage Form
Application:
14/075,965 →
Publication:
US 2014/0072623
Gastric Retentive Gabapentin Dosage Forms and Methods for Using Same
Application:
14/088,058 →
Publication:
US 2014/0135395
Method of Treating Post-Surgical Acute Pain
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
Application:
14/196,143 →
Publication:
US 2014/0186440
Dual Drug Dosage Forms with Improved Separation of Drugs
Controlled Release Dosage Forms
Application:
14/262,622 →
Publication:
US 2015/0030675
Methods of Treatment Using a Gastric Retained Gabapentin Dosage Form
Application:
14/328,580 →
Publication:
US 2015/0157558
Shell-And-Core Dosage Form Approaching Zero-Order Drug Release
Gastric Retentive Dosage Forms for Extended Release of Acamprosate into the Upper Gastrointestinal Tract
Dual Drug Dosage Forms with Improved Separation of Drugs
Pulsatile Gastric Retentive Dosage Forms
Application:
14/838,031 →
Publication:
US 2016/0038411
Gastric Retentive Pharmaceutical Compositions for Treatment and Prevention of Cns Disorders
Gastric Retentive Dosage Forms for Extended Release of Acamprosate into the Upper Gastrointestinal Tract
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
Application:
15/085,574 →
Publication:
US 2016/0206558
Methods of Treatment Using a Gastric Retained Gabapentin Dosage Form
Application:
15/163,491 →
Publication:
US 2016/0263044
Method of Treating Post-Surgical Acute Pain
Application:
15/404,502 →
Publication:
US 2017/0128400
Gastric Retentive Pharmaceutical Compositions for Treatment and Prevention of Cns Disorders
Dual Drug Dosage Forms with Improved Separation of Drugs
Application:
15/422,275 →
Publication:
US 2017/0202817
Shell-And-Core Dosage Form Approaching Zero-Order Drug Release
Application:
15/451,240 →
Publication:
US 2017/0172930
Oral Liquid Compositions
Application:
60/071,865 →
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
Application:
60/294,551 →
Methods of treatment using a gastric retained losartan dosage
Application:
60/335,247 →
Methods of treatment using a gastric retained gabapentin dosage
Application:
60/335,248 →
Modified release formulations of at least one form of tramadol
Application:
60/357,851 →
Gastro-retentive levodopa delivery form
Application:
60/417,829 →
Dosage forms and methods for reducing or eliminating gabapentin-induced adverse side effects
Application:
60/852,534 →
Pulsatile Gastric Retentive Dosage Forms
Application:
60/952,501 →
Pulsatile gastric retentive dosage forms
Application:
60/967,717 →
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-opioid Analgesic and an Opioid Analgesic
Application:
61/035,696 →
Method of Treating Post-Surgical Pain
Application:
61/055,581 →
Gasteric retentive gabapentin dosage forms and methods for using same
Application:
61/065,442 →
Gastric Retentive Pharmacetical Compositions for Treatment and Prevention of Cns Disorders
Application:
61/089,339 →
Gastric Retentive Pharmaceutical Compositions for Treatment and Prevention of Cns Disorders
Application:
61/122,276 →
Gastric Retentive Pharmaceutical Compositions for Immediate and Extended Release of Levosulpiride
Application:
61/238,346 →
Gastric Retentive Pharmaceutical Compositions for Immediate and Extended Release of Acetaminophen
Application:
61/238,374 →
Gastric Retentive Pharmaceutical Compositions for Immediate and Extended Release of Phenylephrine
Application:
61/258,460 →
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of Acetaminophen and Phenylephrine
Application:
61/258,488 →
Gastric Retentive Pharmaceutical Compositions for Extended Release of Polypeptides
Application:
61/267,669 →
Gastric Retentive Pharmaceutical Compositions for Immediate and Extended Release of Levosulpiride
Application:
61/363,174 →
Gastric Retentive Dosage Forms for Extended Release of Acamprosate into the Upper Gastrointestinal Tract
Application:
61/387,368 →
Compositions and Methods for Treating Gastrointestinal Motility Dysfunction
Application:
61/650,451 →
Pharmaceutical Compositions for Extended Release of Azo-Bonded 5-Aminosalicylic Acid Compositions
Application:
61/694,164 →
Liquid Dispensing Device with Electronic Counting Component
Application:
62/092,487 →
Related Assignments
(19)
Other recorded transfers of the patents in this record — the chain of ownership.
Amendment to Employment Agreement
Dec 17, 2009
From: SANCILIO, FREDERICK D.
To: AAIPHARMA INC.
Reel/Frame 023678/0686 →
Amendment and Restated Employment Agreement Between Aaipharma Inc. and Frederick D. Sancilio.
Dec 17, 2009
From: SANCILIO, FREDERICK D.
To: AAIPHARMA INC.
Reel/Frame 023678/0671 →
Security Interest
Apr 2, 2015
From: DEPOMED, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 035355/0039 →
Security Interest
Apr 17, 2017
From: SANCILIO PHARMACEUTICALS COMPANY, INC.; SANCILIO & COMPANY, INC.; BLUE PALM ADVERTISING AGENCY, LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042025/0173 →
Corrective Assignment to Correct the Incorrect Appl. No. 14/240,867 Previously Recorded at Reel: 042025 Frame: 0173. Assignor(S) Hereby Confirms the Security Interest.
Aug 4, 2017
From: SANCILIO PHARMACEUTICALS COMPANY, INC.; SANCILIO & COMPANY, INC.; BLUE PALM ADVERTISING AGENCY, LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 043444/0301 →
Security Interest
Jun 7, 2018
From: SANCILIO PHARMACEUTICALS COMPANY, INC.; SANCILIO & COMPANY, INC.; BLUE PALM ADVERTISING AGENCY, LLC
To: MIDCAP FUNDING IV TRUST, AS AGENT
Reel/Frame 046010/0234 →
Merger
Sep 11, 2018
From: DEPOMED, INC.
To: ASSERTIO THERAPEUTICS, INC.
Reel/Frame 047322/0843 →
Release of Security Interest
Jan 10, 2020
From: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS COLLATERAL AGENT
To: ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.)
Reel/Frame 051482/0107 →
Security Interest
Jan 10, 2020
From: GOLF ACQUIROR LLC
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 051475/0815 →
Assignment of Assignor's Interest
Jan 15, 2020
From: ASSERTIO THERAPEUTICS, INC.
To: GOLF ACQUIROR LLC
Reel/Frame 051521/0536 →
Release of Security Interest
Feb 13, 2020
From: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS COLLATERAL AGENT
To: ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.)
Reel/Frame 051930/0778 →
Release of Security Interest in Patent Collateral Recorded at Reel 051475, Frame 0815
Apr 8, 2020
From: MORGAN STANLEY SENIOR FUNDING INC., AS COLLATERAL AGENT
To: GOLF ACQUIROR LLC
Reel/Frame 052346/0382 →
Patent Collateral Agreement
Apr 10, 2020
From: GOLF ACQUIROR LLC
To: JPMORGAN CHASE BANK, N.A., AS ABL COLLATERAL AGENT
Reel/Frame 052370/0352 →
Security Interest
Apr 10, 2020
From: GOLF ACQUIROR LLC
To: JEFFERIES FINANCE LLC
Reel/Frame 052369/0587 →
Security Interest
Jun 3, 2020
From: ASSERTIO THERAPEUTICS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 052829/0160 →
Release of Security Interest
Oct 7, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: ASSERTIO THERAPEUTICS, INC.
Reel/Frame 061348/0949 →
Merger
Mar 30, 2023
From: GOLF HOLDCO LLC
To: ALMATICA PHARMA LLC
Reel/Frame 063167/0867 →
Merger
Mar 30, 2023
From: GOLF ACQUIROR LLC
To: GOLF HOLDCO LLC
Reel/Frame 063167/0124 →
Termination and Release of Security Interest in Patents
Mar 6, 2025
From: JEFFERIES FINANCE LLC
To: ALMATICA PHARMA LLC
Reel/Frame 070434/0639 →